How does ICH define mean kinetic temperature?

ICH Q1A(R2) defines mean kinetic temperature as “A single derived temperature that, if maintained over a defined period of time, affords the same thermal challenge to a drug substance or drug product.” It is a derived value, not an arithmetic average of the temperatures a container experienced. The definition belongs to licensed-product stability programmes, not to an unstudied research vial.

What does the Mounjaro US label state about storage after first use?

The Mounjaro US Prescribing Information Medication Guide for the multi-dose vial names three discard points: after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses (DailyMed, Mounjaro US PI). Those figures are storage limits on that labeled presentation. They are not a study of a research peptide reconstituted in bacteriostatic water.

What did the secretin excursion study report?

Srinivasan and colleagues stored lyophilized secretin at 25 C and at 25 C/60% RH versus a -20 C control (PMID 25636302). HPLC analyses exhibited a decrease in secretin concentration by week 8 (20 to 27%). At 25 C/60% RH, particle size grew from about 390 nm at day 0 to greater than 2 μm as early as week 1, and reconstitution time increased from about 20 s at day 0 to about 67 s at week 8.

What does EU guidance require before an in-use period is stated?

EMA CPMP/QWP/159/96 corr requires that chemical and physical in-use stability has been demonstrated for x hours or days at y oC before that period is stated. For unpreserved products the period would normally not be longer than 24 hours at 2 to 8 C unless aseptic conditions are validated. For preserved aqueous products the justified period should not normally be greater than 28 days.

What does the bacteriostatic water label say about a dissolved drug?

DailyMed, Bacteriostatic Water for Injection USP, precautions (rev. 08/2019) states: “Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.” The water itself is stored at 20 to 25 C (68 to 77 F) per that label, with benzyl alcohol declared at 0.9% or 1.1% as preservative. No period is set there for a drug dissolved in it.

Is a reconstituted peptide still good after time out of the fridge?

Research use only. This page is scientific background and community-report context on temperature excursions, licensed in-use periods and the limits of a purity certificate. Every compound sold here is supplied strictly for in-vitro research. Nothing here is a protocol, a storage instruction, a recommendation or medical advice.

TL;DR: excursion, in-use periods, and what a purity test cannot show

Research question: What do label criteria and stability studies document about a peptide solution held outside refrigeration? What the published data say: approved GLP-1 labels state one after-first-use window covering fridge and room temperature (Ozempic US PI 56 days at 15 to 30 C or 2 to 8 C; Wegovy EPAR 6 weeks below 30 C), an in-use period is a stability result demonstrated at a stated temperature (EMA CPMP/QWP/159/96 corr), and the excursion datasets are on other molecules (PMID 25636302, PMID 32660375). What the documented searches found: PubMed retatrutide AND (freeze-thaw OR excursion OR reconstitution) on 17 Sept 2026 returned 0 hits, ClinicalTrials.gov v2 retatrutide stability storage 0 studies. What research communities report: in the Reddit corpus we track, 249 question posts in 12 months matched the storage-excursion search, 3 in the 13 to 17 September 2026 window. Reports, not evidence of frequency or potency.

What changes in a peptide solution when it warms up?

Degradation runs faster as a peptide warms, and the liquid form is the unstable one: therapeutic proteins and peptides in liquid dosage forms often show instability during handling as a result of chemical degradation (Angkawinitwong et al., PMID 25565441). In a six-month study of human insulin at 6 C, 25 C and 40 C, temperature had a major impact on deamidation and covalent aggregation rates (Fagan et al., PMID 39725225).

The excursion datasets are on other molecules. Srinivasan and colleagues held lyophilized secretin at 25 C and at 25 C/60% RH against a -20 C control: HPLC analyses exhibited a decrease in secretin concentration by week 8 (20 to 27%), on a lyophilized cake rather than a solution (PMID 25636302). Guyader and colleagues reported a reconstituted trastuzumab biosimilar that maintained its physical and chemical stability for at least 90 days at 4 C or after thermal excursion to 25 C for 72 h (PMID 32660375), one transient result on one biologic. PeptidesDirect does not sell human insulin. PeptidesDirect does not sell secretin. PeptidesDirect does not sell trastuzumab.

What does an excursion mean formally?

ICH Q1A(R2) defines mean kinetic temperature as a single derived value rather than an arithmetic average. ICH Q1A(R2) defines it as “A single derived temperature that, if maintained over a defined period of time, affords the same thermal challenge to a drug substance or drug product.” That belongs to a licensed product's stability programme, not to an unstudied research vial.

What sits behind an in-use period?

An in-use period on an approved label rests on two legs, a stability result at a stated temperature and a microbiological limit. EMA CPMP/QWP/159/96 corr gives the template for the first: “Chemical and physical in-use stability has been demonstrated for x hours/days at y oC.” It caps the second: normally not more than 28 days for preserved aqueous products, 24 hours at 2 to 8 C for unpreserved ones unless aseptic conditions are validated. CDC Injection Safety (17 Sept 2026) dates an opened container from puncture: “the vial should be dated and discarded within 28 days unless the manufacturer states another date for that opened vial.”

PeptidesDirect does not sell semaglutide (Ozempic, Wegovy). PeptidesDirect does not sell tirzepatide (Mounjaro).

Label	Comparator condition	Stated window
Ozempic US PI s.16 (DailyMed, rev. 06/2026)	15 to 30 C or 2 to 8 C	56 days after first use
Wegovy EPAR s.6.3 (EMA)	below 30 C or 2 to 8 C	6 weeks after first use
Wegovy EPAR s.6.3 (EMA)	unrefrigerated, not above 30 C	up to 28 days
Mounjaro multi-dose vial Medication Guide (DailyMed)	room temperature, cumulative	30 days at room temperature, 30 days after first use, or 4 weekly doses

Ozempic US PI s.16 (DailyMed, rev. 06/2026)

Comparator condition: 15 to 30 C or 2 to 8 C
Stated window: 56 days after first use

Wegovy EPAR s.6.3 (EMA)

Comparator condition: below 30 C or 2 to 8 C
Stated window: 6 weeks after first use

Wegovy EPAR s.6.3 (EMA)

Comparator condition: unrefrigerated, not above 30 C
Stated window: up to 28 days

Mounjaro multi-dose vial Medication Guide (DailyMed)

Comparator condition: room temperature, cumulative
Stated window: 30 days at room temperature, 30 days after first use, or 4 weekly doses

None of those windows is a study of a research peptide in bacteriostatic water. Practical notes sit in the storage guide and the reconstituted-vial article.

What can a vial purity test not show?

A purity figure records a powder batch at its test date and says nothing about a solution afterwards. ICH Q1A(R2) sets significant change at a 5% change in assay from its initial value, or a failure to meet the acceptance criteria for potency (s.2.2.7.1), and s.2.1.5 requires validated stability-indicating analytical procedures.

Certificates for this catalog (api.peptidesdirect.io/products/lab-reports, 17 Sept 2026) cover 80 reports across 32 products at a mean purity of 99.55%, retatrutide entries from 11/2025 to 09/2026. Each describes a powder batch at its test date, not a vial after an excursion; lot documents are at /coa.

Bacteriostatic Water for Injection USP is stored at 20 to 25 C (68 to 77 F) and declares benzyl alcohol at 0.9% or 1.1% as preservative (DailyMed, HOW SUPPLIED, rev. 08/2019), and the same label's precautions state: “Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.” No period is set there for a dissolved drug, and a preservative is not a stability result for the solute.

Bacteriostatic Wateraccessories

Made in the EU: sterile bacteriostatic water (WFI-grade water with 0.9% benzyl alcohol), produced in Spain in ISO 13485 and ISO 9001 certified facilities, 0.22 µm sterile-filtered and aseptically filled, near-neutral pH 6.2 to 6.4. The standard solvent for reconstituting lyophilized research peptides, with a lot-specific certificate of analysis. Sealed 10 mL vial, ready to use.

What was not found for retatrutide?

Searches on 17 September 2026 returned no retatrutide excursion or formulation-stability record; retatrutide is the compound most often named in the community posts we track.

PubMed retatrutide AND (freeze-thaw OR excursion OR reconstitution) returned 0 hits. PubMed retatrutide[tiab] AND (stability[tiab] OR storage[tiab]) returned 4 hits, 3 reviews and 1 antidoping detection paper, none a formulation stability or storage study. PubMed (reconstituted peptide) AND (temperature excursion) AND stability returned 2 hits, the two records above, with no retatrutide record. ClinicalTrials.gov v2 retatrutide stability storage returned 0 studies.

Not a storage protocol

The label windows, ICH criteria and excursion papers above belong to the presentations and batches that were studied. They are not a discard rule and not an application protocol for a research vial, and nothing here judges an individual vial.

Products mentioned

Retatrutidemetabolic

Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide that acts on three receptors at once: GLP-1, GIP and glucagon. Supplied as a lyophilized powder for in-vitro research, with a batch-specific third-party certificate of analysis.

Sources

DailyMed. Ozempic US PI s.16, rev. 06/2026. setid adec4fd2-6858-4c99-91d4-531f5f2a2d79.
EMA. Wegovy EPAR product information s.6.3.
DailyMed. Mounjaro US PI, Medication Guide. setid d2d7da5d-ad07-4228-955f-cf7e355c8cc0.
DailyMed. Bacteriostatic Water for Injection USP, HOW SUPPLIED and PRECAUTIONS, rev. 08/2019. setid 87d6e9dc-fe3b-4593-ac9a-d7493d1959c7.
ICH Q1A(R2). Glossary; s.2.1.5; s.2.2.7.1.
EMA. CPMP/QWP/159/96 corr.
CDC. Injection Safety, Clinical Safety Considerations, 17 Sept 2026.
Srinivasan C et al. 2015. Int J Pharm. PMID 25636302.
Guyader GL et al. 2021. J Oncol Pharm Pract. PMID 32660375.
Fagan A et al. 2025. J Pharm Sci. PMID 39725225.
Angkawinitwong U et al. 2015. Ther Deliv. PMID 25565441.
api.peptidesdirect.io/products/lab-reports, 17 Sept 2026.

Research use only. Products sold by PeptidesDirect are supplied strictly for in-vitro laboratory research, not for human or animal administration, and not as medicines. Nothing in this article is a storage, dosing, or medical instruction.